Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 583M 508M 471M 441M 826M 54.99B 831M 5.58B 2.16B 27.06B 2.19B 2.14B 93.98B P/E 2026 *
3x
P/E 2027 * 2.87x
Enterprise Value 583M 508M 471M 441M 826M 54.99B 831M 5.58B 2.16B 27.06B 2.19B 2.14B 93.98B EV / Sales 2026 *
1.27x
EV / Sales 2027 * 1.22x
Free-Float
97.07%
Yield 2026 *
-
Yield 2027 * -
1 day+0.57%
1 week-3.01%
Current month-0.84%
1 month-8.05%
3 months+16.45%
6 months+13.10%
Current year+5.04%
1 week 3.49
Extreme 3.49
3.79
1 month 3.14
Extreme 3.145
4.03
Current year 2.95
Extreme 2.95
5.78
1 year 0.66
Extreme 0.6601
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 2021-03-11
Director of Finance/CFO 44 2026-05-14
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 68 2021-06-03
Chairman 61 2019-03-31
Director/Board Member 56 2019-03-31
Date Insider Type Main position Quantity % Market Cap.
06-15Free

Director

63,481 0.0386%
06-15Free

Director

63,481 0.0386%
06-15Free

Chairman

85,052 0.0517%
Change 5-day change 1-year change 3-year change Capi.($)
+0.57%-3.01%+404.56%-67.31% 583M
-1.36%-4.35%+44.03%+2.44% 281B
-0.45%-0.26%+21.03%-13.36% 66.27B
-0.33%+5.88%+1.98%-8.75% 8.24B
-0.03%-1.37%+29.80%+89.78% 8.13B
-1.92%-1.02%-6.35%+1.40% 4.45B
-2.69%-1.42%-26.97%+37.06% 3.71B
+8.33%+2.08%+0.22%+15.02% 3.42B
+1.84%-0.07%+37.48%+33.84% 2.58B
-1.01%-2.64%+5.02%-28.22% 1.92B
Average +0.29%-1.60%+51.08%+6.19% 38.05B
Weighted average by Cap. -1.06%-4.30%+37.45%+1.70%

Financials

2026 *2027 *
Net sales 459M 401M 371M 347M 651M 43.36B 655M 4.4B 1.71B 21.34B 1.72B 1.69B 74.1B 478M 417M 386M 362M 678M 45.14B 682M 4.58B 1.78B 22.22B 1.8B 1.76B 77.14B
Net income 188M 164M 152M 142M 267M 17.76B 268M 1.8B 699M 8.74B 707M 691M 30.36B 210M 183M 169M 159M 298M 19.8B 299M 2.01B 779M 9.75B 788M 771M 33.84B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
26-06-18 3.540 $ +0.57% 4,942,493
26-06-17 3.520 $ -3.83% 1,629,222
26-06-16 3.660 $ -0.81% 1,825,414
26-06-15 3.690 $ +1.10% 2,004,919
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.540USD
Average target price
6.100USD
Spread / Average Target
+72.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!